- Amylin as a Future Obesity Treatment
-
Dehestani B, Stratford NR, Roux CWl
- KMID: 2524571
- J Obes Metab Syndr.
- 2021 Dec;30(4):320-325.
- doi: 10.7570/jomes21071
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as... -
- CITED
-
- Close
- SHARE
-
- Close
- The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
-
Jakubowska A, Roux CWl, Viljoen A
- KMID: 2552791
- Endocrinol Metab.
- 2024 Feb;39(1):12-22.
- doi: 10.3803/EnM.2024.1942
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on... -
- CITED
-
- Close
- SHARE
-
- Close
